Ascletis Pharma Inc. disclosed via its Next Day Disclosure Return (dated 16 October 2026) that it repurchased an additional 200,000 ordinary shares on-market on 16 October at prices ranging between HKD 5.835 and HKD 6.215, for an aggregate consideration of approximately HKD 1.20 million. The latest transaction represents 0.02% of Ascletis’s 1.05 billion issued shares (excluding treasury shares) outstanding prior to the trade.
Including this purchase, Ascletis has bought back 4.45 million shares for cancellation since 30 June 2026 under the mandate approved on 29 June 2026. The cumulative volume equals about 0.42% of the company’s issued share capital on the mandate date, leaving capacity for a further 101.69 million shares before the 106.14 million-share limit is reached.
Based on the individual volume-weighted average prices disclosed for each repurchase date, total cash deployed for the 4.45 million shares amounts to roughly HKD 34.22 million, implying an average acquisition cost of HKD 7.70 per share.
Despite the ongoing repurchases, Ascletis’s issued share capital remains unchanged at 1.05 billion ordinary shares, supplemented by 5.78 million treasury shares, as the bought-back shares await formal cancellation. In accordance with Hong Kong listing rules, the company is subject to a moratorium on new share issuance or treasury share sales until 15 November 2026.
Comments